Holen Sie sich die Stockscreener-App
1.44
9.92%
0.13
Handel nachbörslich:
1.45
0.01
+0.69%
Schlusskurs vom Vortag:
$1.31
Offen:
$1.32
24-Stunden-Volumen:
1.77M
Relative Volume:
0.49
Marktkapitalisierung:
$63.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.36
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
+23.08%
1M Leistung:
+38.46%
6M Leistung:
+3.60%
1J Leistung:
-71.71%
1-Tages-Spanne:
$1.3005
$1.45
1-Wochen-Bereich:
$1.1422
$1.45
52-Wochen-Spanne:
$0.79
$6.98
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Vergleichen Sie OTLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.44 | 58.19M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Full technical analysis of Outlook Therapeutics Inc. stockMarket Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Outlook Therapeutics Inc. stock prediction for this weekJuly 2025 Opening Moves & Weekly Momentum Stock Picks - newser.com
What does recent volatility data suggest for Outlook Therapeutics Inc.Market Volume Summary & Expert Curated Trade Setups - newser.com
Custom strategy builders for tracking Outlook Therapeutics Inc.Fed Meeting & Fast Gain Stock Tips - newser.com
Will Outlook Therapeutics Inc. (41ON) stock outperform value peersJuly 2025 Snapshot & Reliable Entry Point Trade Alerts - newser.com
Can Outlook Therapeutics Inc. stock continue upward trendJuly 2025 Momentum & Daily Profit Focused Screening - newser.com
News impact scoring models applied to Outlook Therapeutics Inc.2025 Valuation Update & Long Hold Capital Preservation Tips - newser.com
Can Outlook Therapeutics Inc. stock beat analyst upgradesQuarterly Performance Summary & Technical Pattern Based Signals - newser.com
What analysts say about Outlook Therapeutics Inc 41ON stockRisk-Reward Ratio Analysis & Superior Wealth Growth - earlytimes.in
What earnings revisions data tells us about Outlook Therapeutics Inc. - newser.com
Real time pattern detection on Outlook Therapeutics Inc. stockBull Run & Verified Stock Trade Ideas - newser.com
Applying sector rotation models to Outlook Therapeutics Inc.Bear Alert & Verified Trade Idea Suggestions - newser.com
Is Outlook Therapeutics Inc. (41ON) stock good for long term investingEarnings Summary Report & AI Driven Stock Movement Reports - newser.com
Is Outlook Therapeutics Inc a good long term investmentStock Buyback Announcements & Exceptional Trading Strategies - earlytimes.in
How sentiment analysis helps forecast Outlook Therapeutics Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
Outlook Therapeutics Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Weiss Ratings Reaffirms "Sell (E+)" Rating for Oncobiologics (NASDAQ:OTLK) - MarketBeat
How Outlook Therapeutics Inc. (41ON) stock expands through international marketsWeekly Investment Recap & Capital Efficient Trading Techniques - newser.com
Can Outlook Therapeutics Inc. rally from current levels2025 Sector Review & Stock Portfolio Risk Control - newser.com
How Outlook Therapeutics Inc. stock performs in interest rate cyclesQuarterly Profit Review & Weekly High Potential Stock Alerts - newser.com
What is the fair value of Outlook Therapeutics Inc. stock now2025 Volatility Report & Long-Term Growth Stock Strategies - newser.com
Market reaction to Outlook Therapeutics Inc.’s recent newsShare Buyback & Safe Entry Point Alerts - newser.com
How to recover losses in Outlook Therapeutics Inc. stockJuly 2025 Selloffs & Consistent Income Trade Ideas - newser.com
Sentiment analysis tools applied to Outlook Therapeutics Inc.July 2025 Retail & Risk Adjusted Buy/Sell Alerts - newser.com
How Outlook Therapeutics Inc. (41ON) stock moves in volatile trading sessionsJuly 2025 Sentiment & Verified Momentum Watchlists - newser.com
Why Outlook Therapeutics Inc. (41ON) stock is favored by hedge fundsPortfolio Return Report & Low Risk High Win Rate Picks - newser.com
Is Outlook Therapeutics Inc. (41ON) stock attractive for growth fundsEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Outlook To Resubmit Ophthalmic Bevacizumab To The FDA By Year End - insights.citeline.com
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):